Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Carcinoma × Mitomycin × Clear all

Phase

Status

Withdrawn 1 Unknown 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 13 Non-Muscle Invasive Bladder Neoplasms 9 Stomach Neoplasms 7 Carcinoma, Hepatocellular 6 Liver Neoplasms 5 Colorectal Neoplasms 4 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Carcinoma, Transitional Cell 3 Appendiceal Neoplasms 3 Anus Neoplasms 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Peritoneal Neoplasms 2 Lung Neoplasms 2 Gastrointestinal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Anal Canal Carcinoma 2 Uterine Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Solid Neoplasm 1 Pseudomyxoma Peritonei 1 Pancoast Syndrome 1 Ovarian Neoplasms 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Mesothelioma, Malignant 1 Lung Metastases 1

Interventions

Carboplatin 24 Paclitaxel 21 Gemcitabine 17 Cisplatin 16 pembrolizumab 12 Everolimus 8 Docetaxel 8 Radiotherapy, Intensity-Modulated 7 Pemetrexed 7 Fluorouracil 7 130-nm albumin-bound paclitaxel 7 Radiotherapy 6 Nivolumab 6 Cetuximab 6 Panitumumab 5 Cyclophosphamide 5 Bevacizumab 5 Axitinib 5 trebananib 4 lenvatinib 4 Sunitinib 4 Sorafenib 4 Irinotecan 4 Gefitinib 4 volociximab 3 reolysin 3 padeliporfin 3 epothilone B 3 durvalumab 3 Octreotide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02793128 2020-12-22

Olympus

UroGen Pharma Ltd.

Phase 3 Completed

71 enrolled 16 charts 2 FDA

Carcinoma, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡